

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	10/730,476
Filing Date	December 8, 2003
First Named Inventor	Chunying Du
Art Unit	1645
Examiner Name	
Attorney Docket Number	65015

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 801.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 2 of 2

Complete if Known

Application Number	10/730,476
Filing Date	December 8, 2003
First Named Inventor	Chunying Du
Art Unit	1645
Examiner Name	
Attorney Docket Number	65015

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
HJB	C1	PCT International Search Report and The Written Opinion of the International Searching Authority, dated October 20, 2005 for International Application No. PCT/US04/03415.	
	C2	Suzuki, Y., et al., A Serine Protease, HtrA2, Is Released from the Mitochondria and Interacts with XIAP, Inducing Cell Death, Molecular Cell, Molecular Cell, Vol. 8, 613-621, September 2001.	
	C3	Verhagen, Anne, et al., HtrA2 Promotes Cell Death through Its Serine Protease Activity and Its Ability to Antagonize Inhibitor of Apoptosis Proteins, The Journal of Biological Chemistry, Vol. 277, No. 1, 445-454, January 4, 2002.	

Examiner
Signature

HJB

Date
Considered

3/26/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08a (05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 2

Complete if Known

Application Number	10/730,476
Filing Date	December 8, 2003
First Named Inventor	Chunying Du
Art Unit	1645
Examiner Name	Not Yet Assigned
Attorney Docket Number	65015

U.S. PATENT DOCUMENTS

Examiner Initials *	Cite No. 1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code 2 (if known)			
JLW		US-6,110,691	08/29/2000	Wang, et al.	
		US-6,156,535	12/05/2000	Komeluk, et al.	
		US-6,187,557	02/13/2001	Rothe, et al.	
		US-6,489,138	12/03/2002	Zervos	
		US-20020160975	10/31/2002	Alnemri	
		US-20030073829	4/17/2003	Alnemri	
		US-20030157522	08/21/2003	Boudreaault	
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

FOREIGN PATENT DOCUMENTS

Examiner Initials *	Cite No. 1	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T 6
		Country Code 3 - Number 4 - Kind Code 5 (if known)				

Examiner
Signature

Hope Rabinowitz


Date
Considered

3/26/07

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(05-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/730,476
		Filing Date	December 8, 2003
		First Named Inventor	Chunying Du
		Group Art Unit	1645
		Examiner Name	Not Yet Assigned
		Attorney Docket Number	65015
Sheet	2	of	2

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
HR		CILENTI, L., et al., Characterization of a novel and specific inhibitor for the pro-apoptotic protease Omi/HtrA2. The American Society for Biochem and Molecular Bio. Inc., JBC Papers in Press, published on January 15, 2003.	
		JIN, S., et al., CIAP1 and the serine protease HTRA2 are involved in a novel p53-dependent apoptosis pathway in mammals, Genes & Development 17:359-367 (2003)	
		SAVOPOULOS, J.W., et al, Expression, Purification, and Functional Analysis of the Human Serine Protease HtrA2, Protein Expression and Purification 19, 227-234 (2000)	
		VAN LOO, G., et al., The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity, Cell Death and Differentiation, 9:1, 20-26 (January, 2002)	
		YANG, Q., et al., Omi/HtrA2 catalytic cleavage of inhibitor of apoptosis (IAP) irreversibly inactivates IAPs and facilitates caspase activity in apoptosis, Genes and Development, 17:1487-1496 (2003)	
		YANG, Y., et al., The IAP family: endogenous caspase inhibitors with multiple biological activities, Cell Research, 10:169-177 (2000)	

Examiner Signature	<i>Abge Robinson</i>	Date Considered	3/22/07
-----------------------	----------------------	--------------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	5
-------	---	----	---

Complete If Known

Application Number	10/730,476
Filing Date	December 8, 2003
First Named Inventor	Chunying Du
Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	65015

U.S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

**Examiner
Signature**

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Substitute for form 1449A/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	10/730,476
			Filing Date	December 8, 2003
			First Named Inventor	Chunying Du
			Group Art Unit	Unknown
			Examiner Name	Unknown
			Attorney Docket Number	65015
Sheet	2	of	5	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. 1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
[Handwritten signature]		CHAI, J., et al., Structural and biochemical basis of apoptotic activation by Smac/DIABLO, Nature, Vol. 406, August 24, 2000, pp. 855-862	
		CHAI, J., et al., Structural Basis of Caspase-7 Inhibition by XIAP, Cell, Vol. 104, March 9, 2001, pp. 769-780	
		CRYNS, V. AND YUAN, J., Proteases to die for, Genes & Development, Vol. 12, 1998, pp. 1551-1570	
		DU, C., et al., Smac, a Mitochondrial Protein that Promotes Cytochrome c-Dependent Caspase Activation by Eliminating IAP Inhibition, Cell, Vol. 102, July 7, 2000, pp. 33-42	
		ENARI, M., et al., A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD, Nature, Vol. 391, January 1, 1998, pp. 43-50	
		FACCIO, L., et al., Characterization of a Novel Human Serine Protease that has Extensive Homology to Bacterial Heat Shock Endoprotease HtrA and is Regulated by Kidney Ischemia, J Biol Chem, Vol. 275, No. 4, January 28, 2000, pp. 2581-2588	
		GRAY, C., et al., Characterization of Human HtrA2, a novel serine protease involved in the mammalian cellular stress response, Eur. J. Biochem., Vol. 267, 2000, pp. 5699-5710	
		GREEN, D. R., Apoptotic Pathways: Paper Wraps Stone Blunts Scissors, Cell, Vol. 102, July 7, 2000, pp. 1-4	
		HEGDE, R., et al., Identification of Omi/HtrA2 as a Mitochondrial Apoptotic Serine Protease that Disrupts Inhibitor of Apoptosis Protein-Caspase Interaction, J. Biol. Chem., Vol. 277, No. 1, January 4, 2002, pp. 432-438	
		HOLLEY, C. L., et al., Reaper eliminates IAP proteins through stimulated IAP degradation and generalized translational inhibition, Nature Cell Biology, Vol. 4, June 2002, pp. 439-444	
		HSUEH, R., and ROACH, T., Characterization of Cells by Flow Cytometry, Version 1, February 12, 2002	
		HUANG, D. C., and STRASSER, A., BH3-Only Proteins - Essential Initiators of Apoptotic Cell Death, Cell, Vol. 103, December 8, 2000, pp. 839-842	
	HUANG, H., et al., The Inhibitor of Apoptosis, cIAP2, Functions as a Ubiquitin-Protein Ligase and Promotes in Vitro Monoubiquitination of Caspases 3 and 7, J. Biol. Chem., Vol. 275, No. 35, September 1, 2000, pp. 26661-26664		
	HUANG, Y., et al., Structural Basis of Caspase Inhibition by XIAP: Differential Roles of the Linker versus the BIR Domain, Cell, Vol. 104, March 9, 2001, pp. 781-790		

Examiner Signature	[Handwritten Signature]	Date Considered	3/26/07
--------------------	-------------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 5

Complete if Known

Application Number	10/730,476
Filing Date	December 8, 2003
First Named Inventor	Chunying Du
Group Art Unit	Unknown
Examiner Name	Unknown
Attorney Docket Number	65015

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
<i>td</i>		LAZEBNIK, Y., et al., Studies of the lamin proteinase reveal multiple parallel biochemical pathways during apoptotic execution, Proc. Natl. Acad. Sci., USA, Vol. 92, September 1995, pp. 9042-9046	
		LI, F., et al., Control of apoptosis and mitotic spindle checkpoint by survivin, Nature, Vol. 396, December 10, 1998, pp. 580-584	
		LI, W., et al., Structural insights into the pro-apoptotic function of mitochondrial serine protease HtrA2/Omi, Nat. Struct. Biol., Vol. 9, No. 6, June 2002, pp. 436-441	
		LIU, X., et al., Induction of Apoptotic Program in Cell-Free Extracts: Requirement for dATP and Cytochrome c, Cell, Vol. 86, July 12, 1996, pp. 147-157	
		LIU, X., et al., DFF a Heterodimeric Protein that Functions Downstream of Caspase-3 to Trigger DNA Fragmentation during Apoptosis, Cell, Vol. 89, April 18, 1997, pp. 175-184	
		MARTINS, L. M., et al., The Serine Protease Omi/HtrA2 Regulates Apoptosis by Binding XIAP through a Reaper-like Motif, J. Biol. Chem., Vol. 277, No. 1, January 4, 2002, pp. 439-444	
		MILLER, L. K., An exegesis of IAPs: salvation and surprises from BIR motifs, Trends in Cell Biol., Vol. 9, August 1999, pp. 323-328	
		NAGATA, S., Apoptosis by Death Factor, Cell, Vol. 88, February 7, 1997, pp. 355-365	
		PICKART, C. M., Mechanism Underlying Ubiquitination, Annu. Rev. Biochem., Vol. 70, 2001, pp. 503-533	
		RATHMELL, J. C., and THOMPSON, C. B., The Central Effectors of Cell Death in the Immune System, Annu. Rev. Immunol., Vol. 17, 1999, pp. 781-828	
		SAHARA, S., et al., Acinus is a caspase-3-activated protein required for apoptotic chromatin condensation, Nature, Vol. 401, September 9, 1999, pp. 168-173	
		SALVESEN, G. S. and DUCKETT, C. S., IAP Proteins: Blocking the Road to Death's Door, Nat. Rev. Mol. Cell Biol., Vol. 3, June 2002, pp. 401-410	
<i>✓</i>		SHI, Y., A conserved tetrapeptide motif: potentiating apoptosis through IAP-binding, Cell Death and Differentiation, Vol. 9, 2002, pp. 93-95	

Examiner Signature	<i>Arpe Robinson</i>	Date Considered	<i>3/26/02</i>
-----------------------	----------------------	--------------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1448A/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/730,476
		Filing Date	December 8, 2003
		First Named Inventor	Chunying Du
		Group Art Unit	Unknown
		Examiner Name	Unknown
Sheet 4 of 5	Attorney Docket Number	65015	

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
HA		SRINIVASULA, S., et al., A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis, Nature, Vol. 410, March 1, 2001, pp. 112-116	
		SUZUKI, Y., et al., A Serine Protease, HtrA2, is Released from the Mitochondria and Interacts with XIAP, Inducing Cell Death, Molecular Cell, Vol. 8, September 2001, pp. 613-621	
		TAKAHASHI, A., et al., CrmA/SPI-2 Inhibition of an Endogenous ICE-related Protease Responsible for Lamin A Cleavage and Apoptotic Nuclear Fragmentation, Journal of Biological Chemistry, Vol. 271, No. 51, December 20, 1996, pp. 32487-32490	
		THORNBERRY, N. A. and LAZEBNIK, Y., Caspases: Enemies Within, Science, Vol. 281, August 28, 1998, pp. 1312-1316	
		THIELEMANS, K., et al., Strategies for Production of Monoclonal Anti-Idiotypic Antibodies against Human B Cell Lymphomas, Journal of Immunology, Vol. 133, No. 1, July 1984, pp. 495-501	
		VAN LOO, G., et al., The serine protease Omi/HtrA2 is released from mitochondria during apoptosis. Omi interacts with caspase-inhibitor XIAP and induces enhanced caspase activity, Cell Death and Differentiation, Vol. 9, 2002, pp. 20-26	
		VASKOVSKY, V.E. and KOSTETSKY, E. Y., Modified spray for the detection of phospholipids on thin-layer chromatograms, Journal of Lipid Research, Vol. 9, 1968, page 396	
		VERHAGEN, A. M., et al., Inhibitor of apoptosis proteins and their relatives: IAPs and other BIRPs, Genome Bio., Vol. 2(7), Reviews3009, 2001, pp. 3009.1-3009.10	
		VERHAGEN, A. M., et al., Identification of DIABLO, a Mammalian Protein that Promotes Apoptosis by Binding to and Antagonizing IAP Proteins, Cell, Vol. 102, July 7, 2000, pp. 43-53	
		VERHAGEN, A. M., et al., HtrA2 Promotes Cell Death through Its Serine Protease Activity and Its Ability to Antagonize Inhibitor of Apoptosis Proteins, Journal of Biological Chemistry, Vol. 277, January 4, 2002, pp. 445-454	
		WANG, X., The expanding role of mitochondria in apoptosis, Genes and Development, Vol. 15, (2001), pp. 2922-2933	
		WU, G., et al., Structural basis of IAP recognition by Smac/DIABLO, Nature, Vol. 408, December 21/28, 2000, pp. 1008-1012	
		WU, J. W., et al., Structural Analysis of a Functional DIAP1 Fragment Bound to Grim and Hid Peptides, Molecular Cell, Vol. 8, July 2001, pp. 95-104	
		YANG, Y., et al., Ubiquitin Protein Ligase Activity of IAPs and Their Degradation in Proteasomes in Response to Apoptotic Stimuli, Science, Vol. 288, May 5, 2000, pp. 874-877	

Examiner Signature	<i>Ape Robin</i>	Date Considered	3/26/07
--------------------	------------------	-----------------	---------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/730,476
				Filing Date	December 8, 2003
				First Named Inventor	Chunying Du
				Group Art Unit	Unknown
				Examiner Name	Unknown
Sheet	5	of	5	Attorney Docket Number	65015

[illegible]

Examiner Signature	<i>the Baron</i>	Date Considered	<i>3/26/07</i>
-----------------------	------------------	--------------------	----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.